[ad_1]
MONTREAL, Sept. 24, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Firm”) is happy to announce it positioned No. 27 on the 2021 Report on Enterprise rating of Canada’s Prime Rising Corporations.
Canada’s Prime Rising Corporations ranks Canadian firms on three-year income development. Knight earned its spot with three-year development of two,211%.
“We’re honoured to be acknowledged within the high 10% of The Globe and Mail as certainly one of Canada’s Prime Rising Corporations,” mentioned Samira Sakhia, President and Chief Govt Officer of Knight. “The success of the final three years outcomes from our workforce’s outstanding execution on our technique to construct a number one specialty pharmaceutical firm and to broaden Knight’s operations into Latin America. We’re proud to have efficiently launched a Canadian born enterprise onto the worldwide stage and we’ll proceed to work relentlessly to develop our pan-American ex-US footprint in an effort to fulfill our mission of bringing modern and high-quality branded therapies to enhance the well being of sufferers in Canada and Latin America.”
Launched in 2019, the Canada’s Prime Rising Corporations editorial rating goals to rejoice entrepreneurial achievement in Canada by figuring out and amplifying the success of growth-minded, impartial companies in Canada. It’s a voluntary program; firms needed to full an in-depth utility course of in an effort to qualify. In complete, 448 firms earned a spot on this yr’s rating.
The complete listing of 2021 winners, and accompanying editorial protection, is printed within the October subject of Report on Enterprise journal—out now—and on-line.
“As we glance towards the longer term, Canada’s Prime Rising Corporations supply each inspiration and sensible insights for different corporations going through comparable challenges,” says James Cowan, Editor of Report on Enterprise journal. “The entrepreneurs behind these firms are good, tenacious and unwavering of their dedication to their objectives.”
“Any enterprise chief searching for inspiration ought to look no additional than the 448 companies on this yr’s Report on Enterprise rating of Canada’s Prime Rising Corporations,” says Phillip Crawley, Writer and CEO of The Globe and Mail. “Their development helps to make Canada a greater place, and we’re proud to carry their tales to our readers.”
About The Globe and Mail
The Globe and Mail is Canada’s foremost information media firm, main the nationwide dialogue and inflicting coverage change by courageous and impartial journalism since 1844. With award-winning protection of enterprise, politics and nationwide affairs, The Globe and Mail newspaper reaches 6.4 million readers each week in print or digital codecs, and Report on Enterprise journal reaches 2 million readers in print and digital each subject. The Globe and Mail’s funding in modern information science implies that because the world continues to alter, so does The Globe. The Globe and Mail is owned by Woodbridge, the funding arm of the Thomson household.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical firm centered on buying or in-licensing and commercializing modern pharmaceutical merchandise for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical firm. Knight Therapeutics Inc.’s shares commerce on TSX below the image GUD. For extra details about Knight Therapeutics Inc., please go to the corporate’s site at www.gud-knight.com or www.sedar.com.
Ahead-Wanting Assertion
This doc comprises forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, essentially contain dangers and uncertainties that would trigger precise outcomes to vary materially from these contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based mostly to be affordable on the time they have been ready however cautions the reader that these assumptions relating to future occasions, lots of that are past the management of Knight Therapeutics Inc. and its subsidiaries, could in the end show to be incorrect. Elements and dangers, which may trigger precise outcomes to vary materially from present expectations are mentioned in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Data Kind for the yr ended December 31, 2020 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to replace or revise any forward-looking statements whether or not because of new info or future occasions, besides as required by regulation.
[ad_2]
Source